Mass spectrometry involves the measurement of the mass-to-charge ratio of ions.  The technique transforms molecules from a liquid phase to the gas phase and then ionizes the molecules.  The generated ions are focused into a beam and directed to a detector where their mass can be determined.  The masses of the ions and/or their fragments are mass analyzed based on their mass to charge ratio (m/z).  This process identifies the molecules present in Exhaled Breath Condensate (EBC), to determine biomarkers for various lung diseases.  Essentially, mass spectrometry provides the chemical fingerprint of someone's breath to diagnose potential health issues.  Collecting EBC through breathing into a collection device is a non-invasive method compared to traditional lung biopsies or bronchoscopy, making it more patient friendly.

​

Researchers can identify specific molecules including proteins, peptides, and metabolites that may be elevated in certain diseases, potentially serving as biomarkers for research, diagnosis and disease monitoring.  Small molecules such as acetone, urea and others also can be detected.  EBC analysis with MS has been explored for diagnosing conditions like asthma, cystic fibrosis, lung cancer, and even inflammatory lung diseases.

​

Some challenges and considerations of this approach include the possibility that the composition of EBC can be influenced by factors like hydration level, breathing patterns, and environmental conditions.  This may require careful sample collection and standardization techniques.  EBC may contain a complex mixture of molecules, necessitating advanced MS techniques like liquid chromatography – mass spectrometry (LC-MS) or gas chromatography – mass spectrometry (GC-MS) to separate and identify individual components.